Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Item
http://www.wikidata.org/entity/Q41548711
KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyLong non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5pRole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyCorrelation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
P2860

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Item
http://www.wikidata.org/entity/Q41548711
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
@en
type
label
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
@en
prefLabel
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698